Pear Therapeutics, Inc. reaffirmed revenue guidance for the full year 2022. For the year, reaffirmed its $22 million revenue guidance.
Pear Therapeutics, Inc.
Equities
PEAR
US7047231052
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
23/05 | Pear Therapeutics, Inc. Went Out of Business | CI |
08/05 | Combined Liquidation Plan and Disclosure Statement Approved for Pear Therapeutics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+51.85% | 5.93TCr | |
+41.42% | 4.09TCr | |
-5.25% | 4.02TCr | |
-5.16% | 2.87TCr | |
+12.79% | 2.66TCr | |
-20.18% | 1.89TCr | |
+30.88% | 1.25TCr | |
+0.61% | 1.24TCr | |
+25.06% | 1.23TCr |
- Stock Market
- Equities
- PEAR Stock
- News Pear Therapeutics, Inc.
- Pear Therapeutics Reaffirms Revenue Guidance for the Full Year 2022